Redefining the Scholar-Athlete: China Biotech CEOs
The NetEase article, “Redefining the Scholar-Athlete: China Biotech CEOs," featured Russell Reynolds Associates' insight report, created in partnership with BayHelix Group, on key competencies for China biotech CEOs. The article is excepted below.
China's nascent biotech industry is booming. To better understand China's leading biotech CEOs, BayHelix Group and Russell Reynolds Associates had conversations with selected biotech CEOs and investors who shared their most critical challenges and considerations.
This research, along with Russell Reynolds Associates' deep market knowledge, helps illuminate the leadership profiles that have built China's biotech sector to date, and which qualities and experiences will be most essential for the market's continued development and success.
Close to 80 percent of current CEOs are company founders, nearly 75 percent of current CEOs have PhDs
With most coming from R&D backgrounds, these CEOs have deep scientific experience as well as a profound understanding of the China biotech landscape, average tenure is 9.5 years
42 percent of the current biotech CEOs worked for large pharma companies; 66 percent were previously in biotech
To read the full article, click here.
This article has also been featured in the news sites shown below.